DRUG
Liraglutide
Liraglutide will be prescribed following FDA approved packet insert for type 2 diabetes in our test population.
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
Status
Recruiting
Phase
Phase 2
Enrollment
50
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY). The investigators are interested in better understanding the way that this drug affects the metabolism and hormone levels of a person with MODY. Many people with MODY report having gastrointestinal (GI) issues such as an upset stomach. Investigators also are interested in finding out if this drug will help with GI issues. If liraglutide does help with this symptom of MODY, the investigators want to know why this happens. If this drug is effective for participants, the investigators will use participants cells to make human induced pluripotent stem cell (iPSC). This means that the investigators will use participant cells to create what are called stem cells, which are cells in the body that are able to be told what their job is. Investigators will use these cells to see what happens in gastrointestinal (GI) tract.
Full detailed description
The objective of this study is to perform a comprehensive metabolic and hormonal evaluation of individuals with Maturity-onset diabetes of the young (MODY) at baseline and then assess response to initiation of liraglutide. Select individuals will be consented for human induced pluripotent stem cell (iPSC) generation to identify the cellular basis of enteroendocrine cell (EEC) dysfunction. The hypothesis is that heterozygous mutations in MODY-related genes contribute to a range of GI pathologies, including regional disruptions in epithelial identity and disturbances in the function of EECs. Thus, patients with MODY may experience improvement not only in HbA1c and BMI but also in GI symptoms with initiation of GLP-1 receptor agonists. Investigators plan to enroll approximately 50 patients with MODY and obtain baseline metabolic labs and imaging along with enteroendocrine labs before initiating liraglutide and assessing response with repeat labs and imaging. This project will provide further guidance for clinical care and treatment of patients with MODY.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Jun 19, 2025
Study start
May 8, 2025
Primary completion
Aug 2026
Study completion
Jan 2027
Results posted
Not reported
Registry updated
Dec 17, 2025
Outcomes
What the study measures.
Primary outcomes
Blood sugar control - HbA1C
Time frame · Baseline and 3 months after study treatment initiation
Hemoglobin A1c
BMI
Time frame · baseline, 1 month, 2 months, and final study visit 3 months after study treatment initiation
Body mass index; weight and height will be combined to report BMI in kg/m\^2
Secondary outcomes
Metabolic - Blood Sugar
Time frame · Baseline through three months of study treatment
Glycemic patterns observed utilizing a continuous glucose monitor
Enteroendocrine function - GI symptoms
Time frame · baseline, 1 month, 2 months, and final study visit 3 months after study treatment initiation
ANMS Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD)
Enteroendocrine function - insulin
Time frame · baseline and 3 months after study treatment initiation
Fasting and post meal blood serum insulin levels will be assessed
Enteroendocrine function - c-peptide
Time frame · baseline and 3 months after study treatment initiation
Fasting and post meal blood serum c-peptide levels will be assessed
Body fat percentage
Time frame · baseline, 1 month, 2 months, and final study visit 3 months after study treatment initiation
% body fat as identified by DXA
Liver steatosis
Time frame · baseline and 3 months after treatment initiation
MRI to determine liver health
Eligibility
Who can take part.
- Minimum age
- 10 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Diagnosis of MODY via genetic testing * HgbA1c \>6.5% Exclusion Criteria: * History of anaphylaxis to GLP-1 receptor agonists * Already taking GLP-1 receptor agonists * on medications within the stimulant class * have had bariatric surgery * personal or family history of cancer, especially medullary thyroid cancer * personal history of pancreatitis or pathogenic variants associated with increased risk of pancreatitis * known active kidney disease * severe hypoglycemia (glucose \< 50 mg/dL) within 3 months of study enrollment * HbA1c \> 10.0% * episode of diabetic ketoacidosis (DKA) in the past 3 months * are currently pregnant * BMI \< 18.5 kg/m2 and pediatric patients with BMI \< 5th percentile
Study locations
1 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Liraglutide.
NCT IDStudyPhase / statusEnrollmentUpdated
Fibrosis Lessens After Metabolic Surgery
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis
4Moving Biotech · Knee Osteoarthritis · Synovitis of Knee
Phase 2
Active, not recruiting
129
2026-07
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Ohio State University · Obesity & Overweight · Diabetes (DM)
Not applicable
Recruiting
300
2026-07
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Type 2 Diabetes Mellitus · Mild Cognitive Impairment
Not applicable
Completed
396
2026-07
Phase 1
Recruiting
71
2026-07
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
Novo Nordisk · Obesity
Phase 3
Active, not recruiting
78
2026-07
GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation
West China Hospital · Alzheimer Disease · Diabetes Mellitus Type 2
Not applicable
Completed
213,891
2026-07
Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes
Indiana University · Obesity
Not applicable
Enrolling by invitation
125,000
2026-06
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.